(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
-3.26% $ 3.86
Live Chart Being Loaded With Signals
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients...
Stats | |
---|---|
Dzisiejszy wolumen | 16 717.00 |
Średni wolumen | 66 688.00 |
Kapitalizacja rynkowa | 261.60M |
EPS | $0 ( 2024-03-20 ) |
Następna data zysków | ( $-0.470 ) 2024-05-13 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.910 |
ATR14 | $0.0360 (0.93%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-04 | Huang Jane | Sell | 9 375 | Restricted Stock Unit |
2024-04-04 | Huang Jane | Buy | 9 375 | Common Stock |
2024-04-04 | Huang Jane | Sell | 3 347 | Common Stock |
2024-03-01 | Lim Bryant David | Buy | 150 000 | Employee Stock Option (right to buy) |
2024-03-01 | Scherle Peggy | Buy | 150 000 | Employee Stock Option (right to buy) |
INSIDER POWER |
---|
99.32 |
Last 98 transactions |
Buy: 26 942 964 | Sell: 353 466 |
Wolumen Korelacja
Prelude Therapeutics Korelacja
10 Najbardziej negatywne korelacje | |
---|---|
BNIXU | -0.842 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Prelude Therapeutics Korelacja - Waluta/Towar
Prelude Therapeutics Finanse
Annual | 2023 |
Przychody: | $0 |
Zysk brutto: | $-1.17M (0.00 %) |
EPS: | $-2.02 |
FY | 2023 |
Przychody: | $0 |
Zysk brutto: | $-1.17M (0.00 %) |
EPS: | $-2.02 |
FY | 2022 |
Przychody: | $0 |
Zysk brutto: | $-3.04M (0.00 %) |
EPS: | $-2.27 |
FY | 2021 |
Przychody: | $0.00 |
Zysk brutto: | $0.00 (0.00 %) |
EPS: | $-2.43 |
Financial Reports:
No articles found.
Prelude Therapeutics
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers; PRT3645, a brain penetrant molecule that potently and selectively targets CDK4/6; and PRT-K4 that is in preclinical stage for solid tumors. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej